Key result
Kv1.1 channel dysfunction is associated with episodic ataxia type 1 and epilepsy, making it a promising therapeutic target for brain disorders characterized by hyperexcitability.
Why the study?
To clarify the roles of Kv1.1 in and beyond the nervous system, its contribution to episodic ataxia type 1 and seizure susceptibility, and its pharmacological potential as a target for brain disorders with hyperexcitability.
This review highlights the pathophysiological role of Kv1.1 channels in neurological disorders like episodic ataxia type 1 and epilepsy, emphasizing its potential as a therapeutic target.
Answers are grounded in this paper and cite their sources.
Cautions against premature Kv1.1 modulator use in epilepsy or ataxia; leaves open therapeutic translation pending prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
D’Adamo et al. (2020) conducted a review in Kv1.1 Channelopathies (Episodic ataxia type 1, epilepsy). Kv1.1 channel modulation was evaluated. Kv1.1 channel dysfunction is associated with episodic ataxia type 1 and epilepsy, making it a promising therapeutic target for brain disorders characterized by hyperexcitability.
Synapse has enriched 10 related papers. Consider them for comparative context: